BioMarin Pharmaceuticals Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Thank you very much. We're going to have some fun without Akash here. You will have to tell him that we did a good job running the session without him. I just thought I would just share just a few slides before we get into the Q&A that will also give Akash a bit of time to get over here. It is three years now, 1st of December, since I joined BioMarin. We have made a lot of changes, so I am very excited about where the company is right now. These slides will, I think, give you a good perspective of where we are. Obviously, I am going to be making forward-looking statements. For those of you that do not know BioMarin, we are a global rare disease leader at scale.
He made it. Hey, there, Akash.
I made it. That's quite an entrance.
Is there anything you want to say, or shall I just keep going?
No, yeah, I almost got hit by a cab, but that's it. But yes, please go ahead.
Good, good. No, please start with intro remarks.
Okay. Good, good. We are in 80 countries. Next year will be our 30th anniversary. We now have nine approved products. Five of them are in the metabolic condition space. Six of them are first in disease treatments. This year, at the midpoint of our guidance of $3.8 billion-$3.9 billion, we will be at 20% growth. Out of those nine products, four of them, we believe, have the potential to be over a billion-dollar products. This is all built on a base of capabilities and global reach, which allows us, we believe, to continue to create enormous amounts of value for patients and for investors. We have global capabilities end-to-end, from research, development, regulatory, manufacturing, and obviously commercialization in that global footprint. We are really experts at rare disease and finding patients and getting them started on the therapy and keeping them successfully on therapy and getting the benefits.
I am now going to hand over to Brian to go through just two slides on financial performance.
Thanks, Alexander. BioMarin's efforts to strengthen our financial profile over the last couple years are showing up in our results. Using the midpoint of the 2026 revenue guidance, revenue is on track to grow approximately 60% over the last three years. Earnings per share has doubled. The middle panel here stops at 2025. I will share that for 2026. There are a couple of acquisition-related in-process R&D charges coming through the financials, so we did not show 2026 here. But if you look through those, our operational earnings per share over the three-year period is also on track to more than double. That profitability is translating to cash flow, where our operating cash flow has increased by more than five times from 2023 to 2025.
It is that strengthened cash flow performance that helped fund the Amicus acquisition earlier this year, which brought two rare disease medicines, GALAFOLD for Fabry disease and Pombiliti and Opfolda for Pompe disease, into our portfolio. The transaction closed in April, so Q3 was just our first quarter of the combined company results, and we showed that we can continue to add more patients to both of these therapies in BioMarin's hands. This acquisition was highly synergistic. We have identified approximately more than 50% of the non-GAAP operating costs as synergies in the combined business. This integration is operationally on track. We have already pulled forward two of our deleveraging and accretion metrics since closing the transaction earlier this year. Our views of peak revenue for GALAFOLD and Pombiliti and Opfolda are $1.4 billion and $1.2 billion, respectively.
This is approximately a 40% and 20%, respectively, uplift on what some of the prior views of peak were, again, delivering upon the strategic rationale of this transaction. With the synergies, we expect that by the end of this decade, running the Amicus business on the BioMarin platform can generate operating margins of approximately 60%. That cash flow is enabling us to reinvest in the business. I refer to this sometimes as a virtuous cycle, where we believe we can both grow revenue and profitability and simultaneously invest in innovation. I think we're showing that with some of the new additions to our pipeline this year. I'll hand it back to Alexander for that.
Thanks, Brian. Yeah, so let me pick up with your virtuous cycle, Brian. We're taking these at-scale global rare disease player, the capabilities we have here, together with that diversified growth profile and the financial strength that you just saw from Brian's presentation, and we're reinvesting it in growth. We brought four pipeline products into our company in the last 12 months. Here are the four products, and no doubt, Akash, you're going to ask me a lot of questions about each one of these. We got BMN 820 as part of the Amicus acquisition. This is for FSGS, a very interesting indication. It's a phase III asset. We expect the readout in 2028. BMN 333 is an internal asset. It's our long-acting CNP. We're designing this to be, we believe, have the potential to be best in class in achondroplasia and hypochondroplasia.
Importantly, it has phase II readout in patients in 2027. Obviously, you're very familiar with the market size, 24,000 patients globally. BMN 440, we got this as part of the Alesta acquisition. This will be the first oral treatment, we hope, in hypophosphatasia. So a very large, significant market, about 35,000 patients. This is a lot more than an oral therapy in a market that is an injectable market. By being an oral therapy, we believe it can be systemically absorbed and address many of the issues that are currently not addressed by the current enzyme therapies in this disease. Finally, we have BMN 450. This is our most recent acquisition, announced, what, two weeks ago now. This is potentially the first subcutaneous treatment for Fabry disease. Obviously, this is a market we're already now in with GALAFOLD in Fabry disease.
This allowed us to address a larger population, so not just the genetic amenable population. Again, this will be an important advance for patients as a subcutaneous therapy versus the injectable drugs. So, these are four very important pipeline drugs. Let's now talk about, with the final slide, as I say, many, many important catalysts in the coming period. So looking ahead to the remainder of this year and 2027 and into 2028. We have the pending FDA approval of VOXZOGO in hypochondroplasia. This will be, and we're very proud of these milestones, this will be our seventh first-in-disease treatment if we're approved. It's also in front of Europe, and we're potentially also launching it around the world in multiple countries next year. We have the phase II results of 333, the long-acting CNP.
We also have the first patient data for BMN 440, the drug I talked about, in hypophosphatasia. We've got a lot of very, very important milestones coming up and clinical catalysts, together with obviously the ongoing financial strength and growth of our underlying business. With that, Akash, over to you.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
